Cardiff Oncology (NASDAQ:CRDF) Azioni, Quote.MetaTitle.unusual-options

Cardiff Oncology

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Comments

Cardiff Oncology Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO